Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
search
Subscribe
FREE
This site is intended for healthcare professionals
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
Subscribe
FREE
Edition
European
US
Oncology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
AI Framework Revolutionises Brain Tumour Detection
October 2025
DenseWolf-K, a hybrid AI framework, achieved 99.64% accuracy in brain tumour MRI classification, revolutionising medical imaging.
Read more
28 Oct 2025
AI Framework Revolutionises Brain Tumour Detection
DenseWolf-K, a hybrid AI framework, achieved 99.64% accuracy in brain tumour MRI classification, revolutionising medical imaging.
27 Oct 2025
Nivolumab’s Lasting Edge Confirmed in Melanoma Trial
Nivolumab shows lasting melanoma recurrence prevention, with long-term safety, in largest-ever CheckMate 238 trial analysis.
25 Oct 2025
TRIM56 is Key Driver of Liver Cancer Progression
A new study has identified TRIM56, an E3 ubiquitin ligase, as a key activator of the proto-oncogene Src in hepatocellular carcinoma.
24 Oct 2025
Older Age, Not Comorbidity, Drives Poorer Survival in Liver Cancer
A new study has found that it is older age hat is most strongly linked to poorer survival outcomes in liver cancer.
20 Oct 2025
ESMO 2025: Positive Results from OptiTROP Lung04
Sacituzumab tirumotecan improves survival over platinum chemotherapy in EGFR‑mutated NSCLC, OptiTROP‑Lung04 finds.
19 Oct 2025
ESMO 2025: GFH375 Shows Potential Against KRAS G12D Pancreatic Tumours
Early clinical results reveal that the novel KRAS G12D inhibitor GFH375 achieves a 41% response rate and 97% disease control in advanced…
18 Oct 2025
ESMO 2025: DESTINY-Breast11 Trial Results Revealed
The DESTINY-Breast11 phase 3 trial presented at ESMO 2025 revealed that the anthracycline-free neoadjuvant T-DXd-THP regimen achieved a 67.3% pathologic complete response rate.
16 Oct 2025
Skin Cancer Detection Improved for Transplant Recipients
A risk-stratified approach significantly enhanced skin cancer detection after organ transplantation without increasing health care burden.
Loading posts...
1
2
3
…
56
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View